Ironwood Pharmaceuticals
Open
$4.16
Prev. Close
$4.16
High
$4.17
Low
$4.12
Market Snapshot
$675.12M
28.1
$351.41M
100
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
emptyResult
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Recently from Cashu
Ironwood Pharmaceuticals Advances Gastrointestinal Treatments with Innovative Research and Patient-Centric Strategies
Ironwood Pharmaceuticals Drives Innovation in Gastrointestinal Therapeutics In a pivotal step forward in gastrointestinal medicine, Ironwood Pharmaceuticals announces significant advancements in its p…
Ironwood Pharmaceuticals Gears Up for Quarterly Earnings Amid Gastrointestinal Treatment Innovations
Ironwood Pharmaceuticals Focuses on Advancements in Gastrointestinal Treatments Ironwood Pharmaceuticals stands at a pivotal moment as it prepares to release its quarterly earnings report on February…
Ironwood Pharmaceuticals Prepares for Earnings Report Amid Focus on Gastrointestinal Innovations
Ironwood Pharmaceuticals: Advancing Gastrointestinal Care Through Innovation Ironwood Pharmaceuticals prepares to unveil its quarterly earnings report on February 25, 2026. As the company approaches t…
Ironwood Pharmaceuticals Sees Trading Surge, Focuses on Gastrointestinal Therapies Amid Investor Interest
Ironwood Pharmaceuticals Boosts Focus on Gastrointestinal Therapies Amid Trading Surge Ironwood Pharmaceuticals Inc. is currently experiencing a remarkable surge in investor interest, as evidenced by…